These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1699316)

  • 1. Excitatory amino acid antagonists and Parkinson's disease.
    Girault JA; Halpain S; Greengard P
    Trends Neurosci; 1990 Aug; 13(8):325-7. PubMed ID: 1699316
    [No Abstract]   [Full Text] [Related]  

  • 2. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
    Greenamyre JT; O'Brien CF
    Arch Neurol; 1991 Sep; 48(9):977-81. PubMed ID: 1835370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors.
    Matsuyama S; Higashi H; Maeda H; Greengard P; Nishi A
    J Neurochem; 2002 Apr; 81(2):325-34. PubMed ID: 12064480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine-regulated protein phosphorylation in the basal ganglia.
    Ouimet CC; Hemmings HC; Greengard P
    Adv Exp Med Biol; 1988; 235():1-17. PubMed ID: 3067550
    [No Abstract]   [Full Text] [Related]  

  • 5. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
    Fredholm BB; Svenningsson P
    Neurology; 2003 Dec; 61(11 Suppl 6):S5-9. PubMed ID: 14663001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of DARPP-32 in dopamine signal transduction in the striatum].
    Nishi A
    Tanpakushitsu Kakusan Koso; 1998 Dec; 43(15):2172-81. PubMed ID: 9868353
    [No Abstract]   [Full Text] [Related]  

  • 8. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.
    Hemmings HC; Greengard P; Tung HY; Cohen P
    Nature; 1984 Aug 9-15; 310(5977):503-5. PubMed ID: 6087160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
    Brown AM; Deutch AY; Colbran RJ
    Eur J Neurosci; 2005 Jul; 22(1):247-56. PubMed ID: 16029214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors.
    Svenningsson P; Lindskog M; Ledent C; Parmentier M; Greengard P; Fredholm BB; Fisone G
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1856-60. PubMed ID: 10677546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphorylation state of DARPP-32, a third messenger for dopamine, is regulated by in vivo pharmacological treatments.
    Di Luca M; Cimino M; Cattabeni F
    Neurochem Int; 1992 Mar; 20 Suppl():165S-170S. PubMed ID: 1365418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of (-)-stepholidine on protein phosphorylation of a dopamine- and cAMP-regulated phosphoprotein in denervated striatum of oxidopamine-lesioned rats.
    Guo X; Liu J; Zou LL; Jin J; Wang BC; Jin GZ
    Zhongguo Yao Li Xue Bao; 1998 Mar; 19(2):100-3. PubMed ID: 10374628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine- and adenosine-3',5'-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARPP-32) in the adrenal gland: immunohistochemical localization.
    Meister B; Schultzberg M; Hemmings HC; Greengard P; Goldstein M; Hökfelt T
    J Auton Nerv Syst; 1991 Oct; 36(1):75-84. PubMed ID: 1721636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron-specific phosphoproteins in mammalian brain.
    Nestler EJ; Greengard P
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 17():483-8. PubMed ID: 6328931
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin.
    Desdouits F; Siciliano JC; Greengard P; Girault JA
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2682-5. PubMed ID: 7708705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1-Receptor, DARPP-32, and PP-1 in the primate corpus luteum and luteinized granulosa cells: evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin.
    Mayerhofer A; Fritz S; Grünert R; Sanders SL; Duffy DM; Ojeda SR; Stouffer RL
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4750-7. PubMed ID: 11134138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.
    Hara M; Fukui R; Hieda E; Kuroiwa M; Bateup HS; Kano T; Greengard P; Nishi A
    J Neurochem; 2010 May; 113(4):1046-59. PubMed ID: 20236221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, in the substantia nigra.
    Tsou K; Snyder GL; Greengard P
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3462-5. PubMed ID: 8386374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.